FDA decision on experimental Alzheimer's drug expected this week

Lecanemab -- one of the first experimental dementia drugs to appear to slow the progression of cognitive decline -- has shown "potential" as an Alzheimer's disease treatment, according to Phase 3 trial results.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  HEALTH & COVID-19 NEWS Jan 02, 2023 FDA decision on experimental Alzheimer's drug expected this week Lecanemab -- one of the first experimental dementia drugs to appear to slow the progression of cognitive decline -- has shown "potential" as an Alzheimer's disease treatment, according to Phase 3 trial results. More » TOP STORIES Iowa DPH reports 1,403,337 completed COVID-19 vaccine series » COVID-19 cases have risen in Iowa since October » COVID-19 hospitalizations continue to drop » Broadlawns Medical Center reinstates mask requirement » MORE STORIES Flu activity still high but continued to decline before Christmas, CDC data shows » Myths and facts about treating a hangover » 2022 ends with looming risk of a new coronavirus variant, health experts warn » Lack of info on China's COVID-19 surge stirs global concern » MANAGE YOUR ACCOUNT If you'd like to receive some of our other email newsletters, you can tap or click the links below: Be among the first to receive National Breaking News or Local Breaking News as stories break. Catch up on the day's big stories with our Morning Headlines and Afternoon Digest newsletters. Receive our Daily Forecasts or get Severe Weather Alerts sent straight to your email inbox. Manage your email newsletter subscriptions » For the very latest information, download our free apps To ensure email delivery, add newsletters@e.kcci.com to your address book or safe senders list © 2023 Hearst Television Inc. 300 W 57th Street, New York NY 10019 Privacy Notice | Terms of Use | Unsubscribe